JEN collaborates with Eli Lilly on cancer publications

JEN and Eli Lilly presented two posters at the Multidisciplinary Head and Neck Cancer Symposium based on recent research on patients with metastatic squamous cell carcinoma of the head and neck (mSCCHN). The first poster describes utilization of various supportive therapies (e.g., symptom management, infection treatment, nutritional support, depression management) in the population with mSCCHN. Most supportive care use dropped during gaps in systemic treatment, perhaps in association with a decrease in systemic therapy side effects.
See the poster here

The second poster reports on the utilization of the JEN Frailty Index, a marker of functional impairment that can be derived from health claims data, as proxy for patient performance status in order to describe outcomes among mSCCHN patients. Patterns of systemic therapy use and cost of care increased as the JEN Frailty score increased. The results suggest that the JEN Frailty score at the time of initial diagnosis is a strong predictor of costs, time to death and therapy selection, can be used to establish patient status upon diagnosis and should be subjected to further validation.
See the poster here

Recent Activities